Sofocure v Tablet

The human body shows undesired symptoms after taking Sofocure V 400mg/100 mg tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects of Sofocure V Tablet are mentioned below:

• Fever

• Nausea

• Joint pain

• Vomiting

• Fatigue

• Abdominal pain

• Poor appetite

• Itching

• Dark yellow urine & stools

• JaundicePale skin

• Unusual tiredness

• Feeling light-headed

• Difficulty breathing

• Cold hands and feet

Before using the Sofocure V Tablet, carefully read the instructions. As prescribed by your physician, take these. With or without food, take it. This will allow for better absorption. Stop taking them and consult your doctor if you experience any negative effects.  Oral administration is recommended for Sofocure V 400mg/100mg Tablet, a prescription medication for hepatitis. It is recommended that you speak with your healthcare provider before using this tablet. For maximum advantages, it should be taken daily at the same time.

Sofocure V 400mg/100mg Tablet is a prescription-based Hepatitis medicine used in the treatment of the hepatitis C virus. The active ingredients of the Sofocure V are Sofosbuvir and Velpatasvirwhich belong to the drug class of direct-acting antivirals (DAAs). It is taken orally with or without food as per the doctor's advice. Sofocure V Tablet works by eliminating the virus from the human body. In this way, it prevents the infection from spreading to other parts of the body. The required dosage and duration of the medicine are decided by the doctor. This depends on the type of hepatitis being treated. The doctor will check medical history, age, health condition, and the body's response to the treatment before prescribing this medicine. Taking it in the wrong way or overdosing can cause severe side effects. It may take weeks for patients to notice the benefits of the medicine. So do not stop taking this tablet until your doctor says to do so. Sofocure v is given as a combination therapy with other antiviral medications to treat chronic hepatitis C in adults, and it should not be used alone.

It is advised not to miss any scheduled dosage of Sofocure V 400mg/100mg tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

• Go for a liver function test once you start the treatment to ensure normal functioning of the organ.

• Do not share your medicine with other people, as some medicines treat specific genotypes of Hepatitis.

• Some Hepatitis medicines are given in combination with other antiviral drugs. So, it is advised not to use them alone.

• Hepatitis medicines are given to treat HIV/ AIDS patients in some cases. But these medicines are not the proper treatment for this disease.

• It is advised to use effective birth control methods to avoid pregnancy. Some hepatitis drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine.

• It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with hepatitis medicines. There are chances that many drugs can interact, and some drugs should not be used together.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Author undefined (2025). Real‑world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: A systematic review and meta‑analysis. Frontiers in Gastroenterology - https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2025.1511150/full

Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC, Kao JH, Chuang WL, Yu ML (2024). TACR investigators. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infect Dis Ther. - https://pmc.ncbi.nlm.nih.gov/articles/PMC12260621/

Devan, P., Tiong, K. L. A., Neo, J. E., Mohan, B. P., Wijarnpreecha, K., Tam, Y. C. S., Wong, Y. J. (2023). Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct‑Acting Antiviral‑Experienced Hepatitis C Virus Patients: A Systematic Review and Meta‑Analysis. Viruses, 15(7), 1489 - https://pubmed.ncbi.nlm.nih.gov/37515176/

Devan, P., Tiong, K. L. A., Neo, J. E., Mohan, B. P., Wijarnpreecha, K., Tam, Y. C. S., Coppola, N., Preda, C. M., & Wong, Y. J. (2023). Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses, 15(7) - https://pubmed.ncbi.nlm.nih.gov/37515176/

Indian National Association for the Study of the Liver. (2023). Sofosbuvir‑velpatasvir‑voxilaprevir for hepatitis C virus retreatment in difficult‑to‑treat patients: A real‑life observational study from India. (Advance online publication) - https://pubmed.ncbi.nlm.nih.gov/38261859/

Mahmud, S., Hossain, M.B., Haque, E. et al. Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children. Egypt Liver Journal 15, 30 (2025) - https://link.springer.com/article/10.1186/s43066-025-00430-2

Rustam, R., Qaisar, A. A systematic review of sofosbuvir/velpatasvir/voxilaprevir in HCV patients previously treated with direct-acting antivirals. Egypt Liver Journal, 14, 67 (2024) - https://link.springer.com/article/10.1186/s43066-024-00372-1